Washington – President Donald Trump on Wednesday announced he’s nominated Dr. Heidi Overton, a physician and deputy assistant to the president for domestic policy at the White House, to be the next head of the Food and Drug Administration.
Overton, who earned her doctor of medicine from the University of New Mexico, has worked closely with Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services.
In a post on Truth Social, Mr. Trump said she has helped them “to deliver on the MOST TRANSFORMATIVE Health Agenda in History.”
“She is known to take on the HARDEST issues, and bring me solutions that work best for the Country,” he wrote. “Heidi is 'ALWAYS RIGHT,' Secretary Kennedy recently said in the Oval Office! We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES,” he wrote.
“Dr. Heidi will work with Secretary Kennedy and Dr. Oz to RAPIDLY deliver on my priorities of FASTER Cures, INCREASED American Innovation, MAJOR Clinical Trial Reforms, LOWER Drug Prices, and even more MAHA WINS!” he wrote.
Overton was among the few officials in the Oval Office earlier this month when Mr. Trump signed an executive order recommending limits and changes to childhood vaccines.
Overton completed her general surgery residency at Johns Hopkins University School of Medicine and was a White House fellow during Mr. Trump’s first term.
Overton will need to be confirmed by the Senate. The FDA currently has an acting commissioner, Kyle Diamantas, after former commissioner Dr. Marty Makary resigned in May amid tensions at the organization. At the time, one source familiar with the matter told CBS News that Makary was leaving over the internal debate over flavored e-cigarettes, saying that Makary didn’t want to approve the flavored varieties but had been forced to by other members of the administration. Critics of the flavored e-cigarettes worry about the attraction for children.
The Senate is currently reviewing the nomination, with a vote expected next week. The FDA currently has an acting commissioner, Kyle Diamantas, after former commissioner Dr. Marty Makary resigned in May amid tensions at the organization. The nomination is a significant shift in leadership for the agency, considering the recent controversies surrounding flavored e-cigarettes and the concerns raised by Secretary Kennedy regarding their potential impact on children.
This appointment has implications for the agency’s mission to ensure public health and safety, as well as its role in advancing scientific innovation. The FDA’s mandate is to oversee the safety and efficacy of drugs and medical devices, and this change could significantly affect the agency’s strategy and priorities. The agency is grappling with increasing pressure to address issues like drug pricing and access, and this nomination represents a crucial step in those efforts.
This appointment is expected to be a significant event in the world of healthcare, and the implications for the agency’s future direction are substantial.
This comes as the FDA faces increasing scrutiny from lawmakers and the public, demanding greater transparency and accountability in its operations.
The decision to appoint Dr. Overton represents a strategic move by President Trump to bolster the agency’s authority and influence in key policy areas.
Further analysis is required to fully understand the potential consequences of this appointment, including its impact on the agency’s regulatory framework and its ability to effectively address critical health challenges.
The long-term effects of this decision remain to be seen, but it signals a deliberate effort to prioritize specific areas of healthcare focus, potentially influencing the agency’s approach to drug regulation and oversight.
This is a developing story, and we will continue to provide updates as they become available.
– End of Report
Watch Related Video
Source: CBS News
